NHS National Framework for Romiplostim
NHS England
- Value
- £60,480,000
- Published
- 10 Nov 2026
- Deadline
- Not stated
- Procedure
- Open procedure
- Category
- 33600000 — Pharmaceutical products
- Location
- UKC, United Kingdom
- Notice reference
- 106851-2026
Requirements summary
NHS England is planning a national framework agreement for romiplostim, a pharmaceutical product, under an open procedure with an estimated value of GBP 60,480,000 gross (GBP 50,400,000 net). The planned contract period runs from 1 January 2028 to 31 December 2028, with a renewal option extending to 31 December 2030. This is a pipeline notice, and suppliers planning to introduce the molecule or with questions are invited to contact the MPSC New Market Developments Team.
Key requirements
- National framework agreement for romiplostim for NHS England
- Estimated value GBP 60,480,000 gross (GBP 50,400,000 net)
- Contract period 1 Jan 2028 to 31 Dec 2028, with renewal option to 31 Dec 2030
- Delivery to seven English regions: North East, North West, Yorkshire and the Humber, East Midlands, West Midlands, East of England, South East and South West (London not listed)
- Open procedure; suppliers may be SMEs
- Pre-market engagement: suppliers planning to introduce the molecule should contact the MPSC New Market Developments Team by email